This is a randomised controlled trial, looking at the effect of a number of tocilizumab has on those with severe Covid-19 pneumonia. Tocilizumab is a biologic agent which has been used previously in the treatment of inflammatory arthritis.
This is a study which is considered a national priority.
Participants will be randomised into either tocilizumab or a placebo treatment
Who can participate?
Patients will be eligible if they are
- Adults (18 years +)
- Confirmation of SARS-CoV-2 infection by PCR
- SpO2 </= 93% or PaO2/FiO2 < 300 mmHg
- Agree to contraception or abstinence from sex for the duration of and 28 days after the final treatment